Pedro Madureira (Immunethep)

Pedro Madureira (Immunethep)

Biography

Immunethep is a spin-off from the University of Porto, that is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. By addressing a highly conserved virulence factor, Imumunethep’s therapy elicits protective antibodies against all the serotypes of the referred bacterial pathogens, preventing the emergence of strains that are not addressed by current vaccines. Immunethep’s first product, PNV1 (Paragon Novel Vaccine), is now awaiting approval to enter human clinical trials and it promises to be the first vaccine able to prevent multi-bacterial infections from all its serotypes from the womb until elderhood. Doctor Pedro Madureira, co-founder and CSO of the company, will be lecturing on its behalf.

All session by Pedro Madureira (Immunethep)